Early-stage life science fund BioAdvance announced that it has added an array of new companies to its portfolio, investing nearly $3.2 million into companies from the mid-Atlantic region of the U.S.
Two of the firm’s largest investments went to Opsidio, a Bryn Mawr, Penn.-based company developing monoclonal antibodies to treat fibrotic diseases, and New York-based Pillo Health, which is working on an interactive home healthcare hub. Both companies landed $500,000 contributions from BioAdvance.
Get the full story at our sister site, Drug Delivery Business News.
The post BioAdvance drops $3.2m on device, drug bets appeared first on MassDevice.